AR - 医索

找到约 3151 条结果

Tumor Microbiome Differences inEarly-onset versus Average-onsetPancreatic Adenocarcinoma

医客学院 - 会议报告集

Safety, tolerability and efficacy of 21Pb-DOTAMTATE asa targeted alpha therapy for subjects with unresectableor metastatic somatostatin receptor-expressinggastroenteropancreatic neuroendocrine

医客学院 - 会议报告集

Refining Treatment in AdvancedHepatobiliary Cancers

医客学院 - 会议报告集

Randomized phase lllll trial of gemcitabine plusnab-paclitaxel versus. concurrentchemoradiotherapy with S-1 as neoadjuvanttreatment for borderline resectable pancreaticcancerGABARNANCE study

医客学院 - 会议报告集

Ramucirumab plus paclitaxel as switch maintenanceversus continuation of oxaliplatin-based chemotherapyin patients with advanced HER2-negative gastric orgastroesophagealjunction cancerthe ARMAN

医客学院 - 会议报告集

Phasel study of C-CAR031, aGPc3-specificTGFBRllDN armored autologous CAR-T, inpatients with advanced hepatocellularcarcinoma(Hcc)

医客学院 - 会议报告集

Phase ll study of sitravatinib in combination withtislelizumab in patients with advanced biliary tractcancer who have failed to at least 1 prior systemictreatment

医客学院 - 会议报告集

Nivolumab plus ipilimumab vs lenvatinib or sorafenib asfirst-line treatment for unresectable hepatocellularcarcinoma first results from CheckMate 9DW

医客学院 - 会议报告集

NCIETCTN 10476 A Randomized, Phase 2 Study ofcombination Atezolizumab and Varlilumab(CDX-1127) withor without addition of Cobimetinib in Previously TreatedUnresectable Biliary Tract Cancer

医客学院 - 会议报告集

International, open-label phase 2 study of regorafenibplus pembrolizumab in patients with advancedhepatocellular carcinoma previously treated withimmune checkpoint inhibitors

医客学院 - 会议报告集

今日实时热搜